Associate Professor Dominic Wall is Peter Mac's Executive Director of Business Ventures.
This role provides leadership and management for programs and departments relating to both existing and emerging business ventures, specifically: the current Pathology services and an associated business unit - nexomics - which provides specialised accredited medical oncology testing for clinical research, as well the new national Centre of Excellence in Cellular Immunotherapy which was established in 2019 with an $80 million contribution from the Commonwealth Government.
This program intends to provide new means for Australian patients to access innovative cell based immunotherapy products such as CAR-T cells.
He is also the Chief Scientific Officer of Peter Mac’s majority owned and controlled independent and commercial business Cell Therapies Pty Ltd which provides specialised contract manufacturing and testing of cells for human therapy, predominantly in the field of cellular immunotherapy and gene therapy.
Dominic is the responsible person to provide the executive support for all of these businesses to flourish in a public hospital setting.
Dominic has been directly involved in cell therapy manufacturing since the 1990s and was responsible for manufacturing Australia’s first CAR-T products in 2008. Cell Therapies has Australia’s only TGA licence for manufacturing of both commercial and clinical trial CAR-T products, and Dominic carries final accountability for quality and manufacturing of those products.
He has been also involved in pathology service delivery since his training in London at the University of London School of Pathology at Middlesex & UCH, followed by a PhD at the University of Melbourne and a Founding Fellowship in the Faculty of Science in the Royal College of Pathologists of Australasia.
He was responsible for the expansion and re-establishment of specialised pathology services at Peter Mac in 2001, having fully restructured the services, establishing new on-site services for histology and microbiology and establishing a new 24-hour core laboratory service. His technical expertise is in cell-based therapy, immunology and flow cytometry as well as restructure and corporatisation of internal hospital services.
His research interest is in-vivo cell therapy imaging using PET/SPECT and MRI using novel imaging agents to track the activity and life of these cells in patients. He is the current chair of the Legal & Regulatory Subcommittee of the International Society for Cell Therapy (ANZ) and has been the regional president of his professional society (ISCT) twice. His passion is to bring new technologies into life at Peter Mac, such as gene modified cells for therapy which are proving to be potent and effective new treatments for cancer, and which can save lives. Bringing these technologies to Australian patients requires new funding models and new partnerships with other hospitals, companies and government.
Contributing author, Haemostasis Section, in “Laboratory Haematology, an Account of Laboratory Practices”, 1st Edition, Editor I.Chanarin. Churchill Livingstone,1989.
Recent journal articles:
- Gowans EJ, Roberts S, Jones K, Dinatale I, Latour PA, Chua B, Eriksson EM, Chin R, Li S, Wall DM, Sparrow RL, Moloney J, Loudovaris M, Ffrench R, Prince HM, Hart D, Zeng W, Torresi J, Brown LE, Jackson DC. A Phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol 2010 53(4): 599-607.
- Trickett AE and Wall D Regulation of cellular therapy in Australia. Pathology 2011 43(6), pp. 627–634
- Gambell P, Herbert K, Dickinson M, Stokes K, Bressel M, Wall D, Harrison S, Prince HM. Peripheral Blood CD34(+) Cell Enumeration as a Predictor of Apheresis Yield: An Analysis of More Than 1,000 Collections. Biol Blood Marrow Transplant. 2012 [Jan epub]
- Khot A, Dickinson M, Stokes K, Harrison S, Burbury K, Fleming S, Wall D, Gambell P, Prince HM, Seymour J, Ritchie D. A Risk Adapted Protocol For Delayed Administration Of rhG-CSF Following High Dose Chemotherapy And Autologous Stem Cell Transplantation. Clin Lymphoma, Myeloma & Leukemia 2013 13 (1): 42-7.
- Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K, Chen K, Shin M, Wall DM, Hönemann D, Gambell P, Westerman DA, Haurat J, Westewood JA, Scott AM, Kravets L, Dickinson M, Trapani JA, Smyth MJ, Darcy PK, Kershaw MH, Prince HM. Persistence and efficacy of second generation CAR-T cells against the LeY antigen in acute myeloid leukemia. Mol Ther. 2013 Jul 8
- Herbert KR, Gambell P, Link EK, Mouminoglou A, Stokes K, Wall DM, Harrison SJ, Ritchie DS, Seymour JF, Prince HM. Pegfilgrastim compared to filgrastim for cytokine-alone mobilization of autologous hematopoietic stem and progenitor cells. Bone Marrow Transplant. 2013; 48(3):351-6
- Tuch BE, Wall DM. Perspectives - Self-regulation of autologous cell therapies. MJA. 2014; 200(4)
- Tuch BE, Wall DM. Letters - Self-regulation of autologous cell therapies. MJA. 2014; 201(9)
- Massimo Dominici, Karen Nichols, Alok Srivastava, Daniel J. Weiss, Paul Eldridge, Natividad Cuende, Robert J. Deans, John E.J. Rasko, Aaron D. Levine, Leigh Turner, Deborah L. Griffin, Lynn O'Donnell, Miguel Forte, Chris Mason, Edwin Wagena, William Janssen, Robert Nordon, DM Wall, Hong-Nerng Ho, Milton A. Ruiz, Steve Wilton, Edwin M. Horwitz, Kurt C. Gunter. Positioning a Scientific Community on Unproven Cellular Therapies: The 2015 International Society for Cellular Therapy Perspective. Cytotherapy 2015; 17(12) 1663-6.